Meeting
2023 ASCO Genitourinary Cancers Symposium
Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo).
Authors
Laeth George
Cleveland Clinic Foundation, Cleveland, OH
Laeth George , Wei Wei , C. Marcela Diaz-Montero , Allison Martin , Neil Vyas , Arnab Basu , Katy Beckermann , Amanda Nizam , Christopher Eing Wee , Timothy D. Gilligan , Shilpa Gupta , Brian I. Rini , Moshe Chaim Ornstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03126331
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 672)
DOI
10.1200/JCO.2023.41.6_suppl.672
Abstract #
672
Poster Bd #
H4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless
Poster
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
First Author: Bradley Alexander McGregor
First Author: Sylvie Lorenzen
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).
First Author: Michael B. Atkins